Abbott Laboratories (ABT) Total Current Liabilities (2009 - 2026)

Abbott Laboratories (ABT) has 18 years of Total Current Liabilities data on file, last reported at $18.4 billion in Q1 2026.

• For the quarter ending Q1 2026, Total Current Liabilities rose 41.32% year-over-year to $18.4 billion; the trailing twelve-month figure through Mar 2026 stood at $18.4 billion (up 41.32% YoY), and the FY2025 full-year result was $16.5 billion, up 16.52% from the prior year.
• Total Current Liabilities climbed to $18.4 billion in Q1 2026, from $16.5 billion in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $18.4 billion in Q1 2026 to a low of $12.4 billion in Q2 2022.
• A 5-year average of $14.3 billion and a median of $14.0 billion in 2024 frame the typical range for Total Current Liabilities.
• Across the five-year window, Total Current Liabilities fell 10.64% in 2023 and jumped 41.32% in 2026, its largest moves.
• Tracing ABT's Total Current Liabilities over 5 years: stood at $15.5 billion in 2022, then fell by 10.64% to $13.8 billion in 2023, then grew by 2.28% to $14.2 billion in 2024, then advanced by 16.52% to $16.5 billion in 2025, then gained by 11.4% to $18.4 billion in 2026.
• Business Quant data shows ABT's Total Current Liabilities at $18.4 billion in Q1 2026, $16.5 billion in Q4 2025, and $14.6 billion in Q3 2025.